Literature DB >> 9685851

Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination.

T Gotoh1, K Yamada, A Ito, H Yin, T Kataoka, K Dohi.   

Abstract

We examined the effects of a Japanese fermented soybean product, miso, and tamoxifen (TAM), alone and in combination, on N-nitroso-N-methylurea (MNU)-induced rat mammary cancer. Seven-week-old female CD/Crj rats received a single i.v. dose (50 mg/kg body weight) of MNU. After administration of MNU, the rats were divided into 4 groups: regular diet (control), 10% miso diet, regular diet + TAM, and 10% miso diet + TAM. TAM was implanted s.c. in the form of pellets containing 2.5 mg at the same time as MNU was administered. All rats were observed for 18 weeks after MNU administration. Incidence (percentage of rats with tumors) and multiplicity (mean tumors/rat) of mammary tumors were 91% and 4.5 in the control, 77% and 2.4 (P < 0.05) in the 10% miso group, 68% and 1.4 (P <0.01) in the TAM group, and 10% (P < 0.0001 or less) and 0.2 (P < 0.0001) in the 10% miso + TAM group. In the second experiment, the effect of the combination of miso and TAM on established rat mammary tumors was investigated. When the mammary tumors induced by MNU reached 10 to 25 mm, the rats were divided into 3 treatment groups: regular diet, regular diet + TAM, and 10% miso diet + TAM. At 6 weeks after the start of treatment, the mean tumor size in the control and TAM groups was 160% and 141% of the pretreatment value, but a decrease of 85% of the pretreatment value was produced by the combination of miso and TAM, and this was significantly different from both the control and TAM groups (P < 0.01) and P < 0.05, respectively). These results indicate that miso is useful in protecting against mammary cancer and it can be expected to have a potent antitumor effect, especially when used in combination with TAM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685851      PMCID: PMC5921843          DOI: 10.1111/j.1349-7006.1998.tb03288.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  48 in total

1.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Studies on radiation-induced mammary gland neoplasia in the rat. I. The role of the ovary in the neoplastic response of the breast tissue to total- or partial-body x-irradiation.

Authors:  E P CRONKITE; C J SHELLABARGER; V P BOND
Journal:  Radiat Res       Date:  1960-01       Impact factor: 2.841

3.  Energy availability and mammary carcinogenesis: effects of calorie restriction and exercise.

Authors:  C A Gillette; Z Zhu; K C Westerlind; C L Melby; P Wolfe; H J Thompson
Journal:  Carcinogenesis       Date:  1997-06       Impact factor: 4.944

4.  Progression of rat mammary development with age and its relationship to carcinogenesis by a chemical carcinogen.

Authors:  D K Sinha; J E Pazik; T L Dao
Journal:  Int J Cancer       Date:  1983-03-15       Impact factor: 7.396

5.  Interaction of 16 alpha-[125I]iodo-estradiol with estrogen receptor and other steroid-binding proteins.

Authors:  R B Hochberg; W Rosner
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

6.  Genistein, a specific inhibitor of tyrosine-specific protein kinases.

Authors:  T Akiyama; J Ishida; S Nakagawa; H Ogawara; S Watanabe; N Itoh; M Shibuya; Y Fukami
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

7.  Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet.

Authors:  H Adlercreutz; H Honjo; A Higashi; T Fotsis; E Hämäläinen; T Hasegawa; H Okada
Journal:  Am J Clin Nutr       Date:  1991-12       Impact factor: 7.045

8.  Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle.

Authors:  R L Sutherland; M D Green; R E Hall; R R Reddel; I W Taylor
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

Review 9.  Use of tamoxifen for breast cancer: twenty-eight years later.

Authors:  I A Jaiyesimi; A U Buzdar; D A Decker; G N Hortobagyi
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

Review 10.  Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis.

Authors:  T Fotsis; M Pepper; H Adlercreutz; T Hase; R Montesano; L Schweigerer
Journal:  J Nutr       Date:  1995-03       Impact factor: 4.798

View more
  6 in total

1.  Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.

Authors:  Norman C Peterson; Matthew D Servinsky; Archie Christian; Zhongsheng Peng; Weiping Qiu; Jill Mann; John Dicello; David L Huso
Journal:  Carcinogenesis       Date:  2005-04-28       Impact factor: 4.944

2.  Inhibitory effects of O-methylated isoflavone glycitein on human breast cancer SKBR-3 cells.

Authors:  Bo Zhang; Jun-Ping Su; Yang Bai; Jie Li; Yong-Hong Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.

Authors:  Neela Guha; Marilyn L Kwan; Charles P Quesenberry; Erin K Weltzien; Adrienne L Castillo; Bette J Caan
Journal:  Breast Cancer Res Treat       Date:  2009-02-17       Impact factor: 4.872

4.  A high-fat diet increases the incidence of mammary cancer inc-Ha-ras proto-oncogene transgenic rats.

Authors:  Mie Magaki; Hiroko Ishii; Aya Yamasaki; Yurika Kitai; Saeda Kametani; Reiko Nakai; Alexander Dabid; Hiroyuki Tsuda; Takamasa Ohnishi
Journal:  J Toxicol Pathol       Date:  2016-12-08       Impact factor: 1.628

5.  Beneficial biological effects of miso with reference to radiation injury, cancer and hypertension.

Authors:  Hiromitsu Watanabe
Journal:  J Toxicol Pathol       Date:  2013-07-10       Impact factor: 1.628

Review 6.  Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary.

Authors:  Mark J Messina; Charles E Wood
Journal:  Nutr J       Date:  2008-06-03       Impact factor: 3.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.